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Abstract
Background Immunonutrition is assumed to enhance
immune system function. In surgical patients, it is sup-
posed to reduce postoperative complications. However,
results of recent clinical trials have been puzzling and have
not supported this theory.
Aim The aim of our study was to evaluate the value of
enteral and parenteral postoperative immunonutrition.
Methods After initial evaluation of 969 patients, the
intent-to-treat analysis included 776 patients (female 407,
male 466, mean age 61.1 years) undergoing gastric or
pancreatic resections between 2001 and 2009. All patients
were randomly assigned after surgery to one of the fol-
lowing groups: standard enteral nutrition (SEN), immuno-
modulating enteral nutrition (IMEN), standard parenteral
nutrition (SPN), or immunomodulating parenteral nutrition
(IMPN). All malnourished patients received preoperative
parenteral nutrition. Number and type of postoperative
complications, length of hospitalization (length of stay
[LOS]), and vital organ function were assessed.
Results No statistically significant differences were
observed in well-nourished patients, during either enteral
or parenteral intervention, independent of the type of
intervention (standard or immunomodulating). However,
analysis of the malnourished group revealed the positive
impact of enteral immunonutrition on reduction of post-
operative complications (28.3 vs. 39.2 %, respectively;
p = 0.043) and LOS (17.1 and 13.1 days, respectively;
p \ 0.05) compared with a standard enteral diet. The
cross-analysis of SEN, IMEN, SPN, and IMPN was
insignificant.
Conclusions The type of postoperative nutrition was of
no importance in well-nourished patients. However, in
malnourished patients, enteral immunonutrition helped to
improve treatment outcome. These findings suggest its use
as a method of choice during the postoperative period.
Introduction
Only a few factors may influence results of surgery to such
an extent as malnutrition. It complicates wound healing,
increases the rate of postoperative infections, and lengthens
hospital stay. These outcomes are consequences of the
destruction of immune function, amplifying the response to
stress and organ dysfunction [1].
Nutritional therapy has been used in the postoperative
period for over 100 years, since Kausch administered
intravenous glucose solution to help his patient’s recovery
[2]. However, the history of nutritional support as we know
it nowadays began with the invention of parenteral nutri-
tion by Dudrick et al. [3]. Intravenous admixtures proved
effective not only in maintaining health status, but also in
safeguarding growth. This medical approach irreversibly
changed the perception of perioperative care. However,
Buzby et al. [4] and the Veteran Affairs Trial [5] high-
lighted the consequences of hyperalimentation in well-
nourished patients, indicating a reduction in complications
of up to 20 %, but only in malnourished patients. These
studies clarified the perspective of perioperative care and
switched a proportion of nutritional intervention to the
more physiological, less expensive, and safer enteral
feeding [4, 5].
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It took another decade to set the criteria for the selection
of the proper feeding route. Nowadays, leading scientific
societies, ASPEN (American Society for Parenteral and
Enteral Nutrition) and ESPEN (European Society for
Clinical Nutrition and Metabolism), agree that enteral
nutrition should be used as the method of choice in peri-
operative treatment [6, 7]. Further studies concentrated on
pharmaconutrition: formulas that can be used not only to
deliver basic nutrients, but also to influence vital organs
and systems to improve the outcome of therapies. One form
of pharmaconutrition, aiming at improvement of immune
function, was called immunomodulating or immunostim-
ulating. These diets, both parenteral and enteral, included
amino acids (arginine and glutamine), lipids (omega-3 fatty
acids), micronutrients (vitamins C and E), and nucleotides.
Soon after their implementation, some authors observed
their encouraging influence on the outcome of surgery,
which raised new hope for surgical patients [8–10]. Con-
troversy soon began, and the actual value of immuno-
modulating formulas for surgical and critically ill patients
was examined. The positive effects of immunodiets
observed in experimental models were often denied by
clinical results, far more important for clinicists [11]. In
contradiction to Braga et al. [8]. or Gianotti et al. [9],
Senkal et al. [10]. and Lobo et al. [11]. revealed that enteral
immunodiets bore no advantage over standard enteral
nutrition (SEN) when a peptide diet was used; other
authors noticed analogous results. Furthermore, most
research performed in well-nourished individuals failed to
demonstrate the quantifiable efficacy of immunomodulat-
ing diets [11–13].
These outcomes were difficult to match because of the
heterogeneity of study populations, study designs, sample
quantities, and systematic approaches.
To completely address these uncertainties and to verify
the value of immunonutrition in surgical patients, ran-
domized well-designed trials were conducted in a tertiary
surgical center between 2001 and 2009. Results of these
trials were partially published in medical journals, but have
never been presented as a summary [12–15].
Methods
Study design
We conducted a randomized, not blinded (due to obvious
differences in enteral and parenteral routes), controlled
study in order to evaluate the impact of enteral and par-
enteral immunonutrition on postoperative complications in
surgical patients. The study was conducted in the tertiary
surgical center—the 1st Department of General and
Oncology Surgery, Jagiellonian University School of
Medicine, Cracow, Poland—and was performed between
January 2001 and December 2009.
The research was planned to test the hypothesis that
immunonutrition would decrease the occurrence of surgical
and non-surgical complications after gastrointestinal (GI)
surgery. The secondary objectives included evaluation of
effects of nutritional intervention on morbidity and mor-
tality, length of hospital stay (LOS), and vital organ
function.
Patient characteristics and inclusion/exclusion criteria
A total of 969 patients were initially assessed for partici-
pation in the study; 96 patients were unable to meet
inclusion criteria and were excluded after initial assess-
ment. The intent-to-treat (ITT) analysis of 776 patients
(female 407, male 466, mean age 61.1 years) who under-
went gastrectomy (subtotal or total resection) or pancreat-
oduodenectomy (subtotal or total) with lymph node
excision were enrolled in the trial. The inclusion criteria
included good overall status (Karnofsky [80, Eastern
Cooperative Oncology Group [ECOG] grade 0 or 1); the
absence of cancer dissemination or severe associated dis-
eases (cardiac, pulmonary, renal, liver failure, chronic
obstructive pulmonary disease [COPD], coronary aortic
bypass graft, etc.); no history of known aversions or
intolerance to analyzed substances. Patients with metastatic
or unresectable cancer, who were pregnant or in poor
general health (Karnofsky \80, ECOG [ 1), with recent
history of severe heart, lung, kidney, or liver failure, with
history of allergies or drug intolerance were excluded.
Malnutrition was defined as either of the following: unin-
tentional weight loss of at least 10–15 % within
3–6 months before admission or body mass index (BMI)
\18 kg/m2. Respective groups of patients were compara-
ble with each other in terms of sex, age, type of surgery,
BMI, weight loss, serum albumin, and total lymphocyte
count (TLC) on admission and blood transfusion.
Randomization and allocation of patients
After tumor resection, individuals who met the eligibility
norms were intraoperatively allocated to either of four
groups using sealed envelopes containing computer-gen-
erated distribution numbers. A 2 9 2 factorial scheme was
used with the subsequent groups: SEN, immunomodulating
enteral nutrition (IMEN), standard parenteral nutrition
(SPN), and immunomodulating parenteral nutrition
(IMPN) in two parts of the research. In the third part, in
which enteral intervention was assessed, patients were
randomized into SEN or IMEN groups. The CONSORT
(Consolidated Standards of Reporting Trials) diagram
(Fig. 1) shows the flow of participants through the study.
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Clinical management
In contrast with well-nourished patients, who underwent
surgery without preoperative nutritional support, all
malnourished patients received intravenous nutrition the
fortnight before surgery. Protein and energy demands
were calculated using the nitrogen to body weight (b.w.)
ratio (0.15 g N/kg b.w.) and the non-protein energy
proportion (Q = 150 kcal/g N). The 10 % amino acid
solutions, 10–40 % glucose, and 10–20 % lipid emul-
sions, trace elements (Aminoplasmal, Glucose and
Lipofundin MCT/LCT B and Tracutil, B Braun, Ger-
many), vitamins (Cernevit, Baxter, USA), and electrolyte
solutions were used to prepare all-in-one bags at the
pharmacy. The central intravenous catheter was implan-
ted in the subclavian or jugular vein before the onset of
therapy. The tip location was confirmed by chest X-ray.
The same type of intravenous admixture as given pre-
operatively was provided to each patient during the
postoperative period up to postoperative day 7, or longer
in case of complications.
The selection of parenteral instead of enteral feeding
during the preoperative period, which has been endorsed
for many years, was the consequence of the absence of
those guidelines at the time of study preparation (2001) and
the wide acceptance of that kind of perioperative approach
in local surgical units (Polish national standards).
During surgery (gastric or pancreatic resection), an
enteral feeding tube (Flocare Nutricia Ltd., 140 cm length)
was inserted into the first intestinal loop, 15–20 cm below
the nethermost anastomosis. The surgical team included at
least two skilled general and oncological surgeons, and the
anesthesiology team comprised four people.
Preceding surgery, BMI, weight loss, full blood count
with TLC, albumin and pre-albumin concentration, liver
and kidney tests were assessed.
On postoperative day 1, 3, and 8, the following assess-
ments were made: full blood count with TLC, serum
albumin and pre-albumin concentrations, liver and renal
function, quantity of diet administered, and tolerance.
Assessments were performed by physicians and nurses.
The energy and protein requirements during the
postoperative period were calculated using the same
method as during the preoperative intervention. Enteral
feeding was started 6 h after the procedure, with 5 %
glucose solution at the rate of 20 ml per h for the first
12 h, followed by infusion of Peptisorb (SEN group;
Nutricia Ltd., Poland) or Reconvan (IMEN group;
Fresenius Kabi, Poland) at the rate of 20 ml/h on day 1,
50 ml/h on day 2, 75 ml/h on day 3, and 100 ml/h
thereafter. The whole intervention lasted 1 week. Diet
ingredients are presented in Table 1. Infusion devices
were used to administerr the diet for 20–22 h, with a
2–4 h rest period. An oligopeptide, isocaloric diet was
Assessed for eligibility (n= 969) 
Excluded  for not meeting inclusion 
criteria (n= 96) 
Discontinued intervention 
(n= 1) 
Poor tolerance (n=5) 
SEN Allocated to intervention 
(n=  347) 




Poor tolerance (n=2) 
IMEN Allocated to intervention 
(n= 343) 








Poor tolerance (n=0) 
SPN Allocated to intervention 
(n= 90) 




Poor tolerance (n=0) 
IMPN Allocated to intervention 
(n= 93) 




Fig. 1 CONSORT diagram showing the flow of participants through
each stage of the trial. CONSORT Consolidated Standards of
Reporting Trials, IMEN immunomodulating enteral nutrition, IMPN
immunomodulating parenteral nutrition, ITT intent-to-treat popula-
tion, SEN standard enteral nutrition, SPN standard parenteral nutrition
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selected as a control because of previous high tolerance
in the small intestine. Infusion pumps were used to
guarantee volume and speed control.
Primary objective (primary endpoint)
The primary objective of this study was to assess the
influence of immunomodulating nutrition on postoperative
complications in surgical patients. The ratio of postopera-
tive complications was nominated as the primary outcome
measure, with the hypothesis that the routine use of im-
munodiets in the postoperative period reduces the number
of infectious and surgical complications. Definitions of
complications are presented in Table 2.
Secondary objectives (secondary endpoints)
The secondary objectives included LOS, immune system
function (clinical observations and TLC), assessment of
liver and renal function, and treatment compliance. Fur-
thermore, operational time, intra-operative blood loss,
blood transfusions, and the necessity for re-operation were
recorded. Post-operative mortality was defined as any fatal
outcome within 31 days after hospitalization. The length of
postoperative stay was number of days from the date of
operation until the date of discharge. Albumin solutions
were not used as standard treatment.
Sample size and statistical analysis
The sample size was calculated using SamplePowerTM,
version 16–19 (SPSS Inc., Chicago, IL, USA). A general
estimation was made for each study: the total rate of
complications after upper GI surgery described by previous
studies was approximately 40 %. To detect a 50 %
reduction triggered by immune enteral nutrition, more than
82 patients should be randomized to each of the two related
arms (alpha = 0.05 two-sided, power = 0.80). We
assumed a drop-out rate of 15 %; therefore, 200 patients







Energy (kcal) 100 125 100
Amino acids (g) 4.0 7.5 5.5




Sugars (g) 1.7 0.7 0.7
Lactose (g) 0.1 \0.025 0.15
Total fat (g) 1.7 4.1 3.3
Saturated (g) 1.0 2.6 3.3
MCT (g) 0.8 1.5 1.2




100 (4.3) 134 138
Potassium mg
(mmol)
150 (3.8) 263 207
Chloride mg
(mmol)
125 (3.5) 139 141
Calcium mg
(mmol)
80 (2.0) 67 80 (2.0)
Phosphorus
(mg)
72 (2.3) 67 60
Magnesium
(mg)
23 (0.9) 28 25
Iron (mg) 1.6 1.0 1.33
Zinc (mg) 1.2 1.0 1.2
Copper (mcg) 180 338 133
Manganese (mg) 0.33 0.63 0.63






















Thiamine (mg) 0.15 0.19 0.2
Riboflavin (mg) 0.16 0.31 0.16


















Biotin (mcg) 4.0 5.0 5.0
Vitamin C (mg) 10.0 25 6.7
Choline (mg) 37 46 26.7
Taurine (mg) 10 13 13
Glutamine (g/l) – 10.1 10.2
Arginine (g/l) – 7.2 6.7
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were needed. The figures were investigated on an ITT basis
using SPSS v.14 software. The differences in proportions
amid groups were assessed using the Chi squared test, and
Yates correction was implemented if any of the probable
incidences were \5. Continuous data were studied using
the Mann–Whitney U test. Differences at p \ 0.05 were
considered statistically significant.
Ethics and consent
The Ethics Committee of Jagiellonian University sanc-
tioned the study (KBET/91/L/2004). It was not possible to
obtain approval in 2001, as the Ethics Committee did not
participate in such activities beforehand. Patients were
registered by one of two investigators (SK, KS). Written
approval was acquired from each participant before
acceptance. The study was carried out following the uni-
versal ethical endorsements stated in the Helsinki
Declaration and was recorded in the Clinical Trials Data-
base (NCT00576940).
Role of sources of funding
The study was performed with no outside sponsorship.
Results
Participants were adequately matched for age, sex, weight
loss, BMI, type of operation (stomach/pancreas resection),
TLC, and serum albumin (indicators of nutritional state).
The number of patients who were operated on for gastric
and pancreatic neoplasm, as well as patients within both
groups, was comparable. The ratio of resection types (sub/
total excision) did not differ between groups.
During preoperative intravenous feeding in malnour-
ished patients, each study group received a comparable
level of energy, proteins, and micronutrients.
Postoperative follow-up
There were no noteworthy dissimilarities between the
enteral groups in the tube feeding delivery, either in the
malnourished or the well-nourished group. For the purpose
of this research, the observation was completed on post-
operative day 8, after a full 7 days of enteral feeding, but
the mean length of intervention in the SEN and IMEN
group was 8.4 (±1.2) days and 8.6 (±1.4) days. The mean
interval of intravenous nutrition was 7.9 (0.8) days for SPN
and 8.1 (1.0) days for IMPN.
Compliance was similar amid malnourished patient
groups, protocol violation due to the full dose of diet not
being delivered was the reason for premature cessation in
eight patients (SEN-1, IMEN-2), which accounted for
\1 % of all patients. The planned delivery reached 80 %
of those originally prescribed. The average quantity of
blood units was 1.7 in SEN and 1.6 in IMEN, which was
not significant (p = 0.42).
Detailed analyses of postoperative complications are
presented in Tables 3, 4, 5 and 6.
The LOS differed between the two study groups and
extended up to 17.1 days (standard deviation [SD] 12.2) in
the SEN group and 13.1 days (SD 13.8) in the IMEN group
(p = 0.006) in malnourished patients. In the same group,
there were significant dissimilarities in infectious compli-
cations, which occurred in 60 patients (39.2 %) in the SEN
group and 43 (28.3 %) in the IMEN group (p = 0.04).
Differences were also detected in morbidity (47.1 vs
33.5 %; p = 0.01) and mortality (5.9 vs 1.3 %; p = 0.03).
In well-nourished patients, the median LOS was 12.4
(SD 5.9) days in the SEN group and 12.9 (SD 8.0) days in
Table 2 Definitions of complications
Complication Definition
Wound infection Purulent exudate in the wound with positive
bacterial culture
Abdominal abscess Collection of pus confirmed by percutaneous
drainage or at reoperation
Pneumonia Clinical signs of pneumonia and/or
radiographic evidence (both required to
diagnose) or positive culture of tracheal
aspirate or blood or brushing
Urinary tract
infection
Clinical symptoms and the presence of bacteria
in urine ([100,000 colony-forming units/ml)
Bacteremia Positive blood culture
Infection of venous
catheter
Local signs of inflammation, and/or the
isolation of pathogen organisms in culture
Sepsis Fever [38 C or hypotension (\90 mm Hg
systolic BP) or oliguria (\20 ml/h) along with
positive blood culture
Wound dehiscence Any dehiscence of the fascia [3 cm
Bleeding Necessity of blood transfusion (C2 U)
Anastomotic leak Positive dye-swallow or contrast-swallow test
Respiratory tract
failure
Presence of dyspnoea and respiratory rate [35
breaths/min or PaO2 \70 mm Hg
Circulatory
insufficiency
Unstable BP requiring use of extra fluids or
cardiac stimulants
Renal failure Necessity of haemodialysis
Hepatic
dysfunction
Increased serum bilirubin (2–3 times above
baseline) or hepatic enzyme level (3–4 times
above baseline)
Pancreatic fistula Drain output of any measurable volume of fluid
on or after postoperative day 3 with an




Necessity for nasogastric suction for C8 days
after surgery
BP blood pressure
World J Surg (2014) 38:803–812 807
123
the IMEN group (p = 0.42). Complications were detected
in 21 patients (23.1 %) in the SEN group and 23 (25.2 %)
in the IMEN group (p [ 0.05). Four (4.4 %) patients in the
SEN group and four (4.4 %) in the IMEN group had sur-
gical complications (p [ 0.05).
Blood transfusions were necessary in 12 well-nourished
patients in the SEN group and 11 in the IMEN group; the
median numbers of transfused units were 2.5 in SEN and 2
in IMEN (interquartile range [IQR] 1–3.5 and 1–5,
respectively).
In these patients, LOS was similar in both groups: 12.4
(SD 5.9) days in the SEN and 12.9 (SD 8.0) days in the
IMEN (p = 0.42) groups. Complications were noted in 21
(23.1 %) patients in the SEN and 23 (25.2 %) in the IMEN
groups. Infective complications were detected in 23
patients in the SEN group and 21 in the IMEN group.
Well-nourished patients administered parenteral and
enteral nutrition had a morbidity rate of 36 %; the occur-
rence of specific complications was similar among all
groups (Table 4). Infectious complications were detected
in 28 of 102 patients on standard diets and in 25 of 103
patients receiving immuno-formula (odds ratio [OR] 0.81;
95 % CI 0.43–1.50) (Table 5). Furthermore, there were no
dissimilarities amid infectious complications between
those receiving enteral nutrition (25 of 100 patients) and
those receiving parenteral formulas (28 of 105, OR 1.14,
95 % CI 0.61–2.14). Neither the immunodiet nor enteral
nutrition affected secondary outcome measures, including
morbidity, mortality, and LOS.
Serum pre-albumin, albumin, and TLC levels were
secondary endpoints. The first two were used to assess
visceral protein synthesis and the restoration of nutritional
status. However, the study did not indicate any differences
among groups, as demonstrated in Table 6. Significant
differences were found only in TLC on postoperative day
3, when the mean number of lymphocytes was higher in the
IMEN than the SEN group (p = 0.011), which was not
reflected in postoperative clinical course.
No differences were recorded in hepatic and renal
function. These were assessed by clinical status and labo-
ratory tests. The mean concentrations of aspartate amino-
transferase (SGOT), alanine aminotransferase (SGTP),
blood urea nitrogen (BUN), and creatinine concentrations
did not differ.
Discussion
Modern surgery tries to reduce the rate of postoperative
complications by concentrating more on technical aspects
and less on metabolic aspects. The latter probably repre-
sents the only hope for improvement in the discipline, as
there are not many opportunities for further improvement
from the technical point of view. It is a holistic approach
that gives hope for improvement. Nowadays, the multi-
modal approach to perioperative care should include
analgesia, physiotherapy, aseptics, antiseptics, anticoagu-
lants, infusion therapy, nutritional support, and many other
therapeutic options. Nutritional intervention matters the
most, as the worsening of nutritional status has been
acknowledged as a crucial factor influencing surgical out-
comes [1].
The place of pre- and postoperative nutrition is no
longer in question; particularly since it has been confirmed
that, in severely malnourished individuals scheduled for
major GI surgery, it was advantageous to postpone surgery
for up to 10–14 days and to administer nutritional support,
preferably with enteral diets [6]. From the surgical point of











OR (95 % CI) p value
Rate of infectious
complications
23 (27) 20 (24) 0.842 (0.420–1.687) 0.627 19 (23) 24 (29) 1.347 (0.671–2.706) 0.401
Overall morbidity 33 (39) 25 (30) 0.666 (0.351–1.265) 0.214 29 (35) 29 (35) 0.982 (0.519–1.857) 0.995
Morbidity (30 days
post-surgery)
37 (41) 28 (33) 0.655 (0.353–1.345) 0.216 32 (38) 32 (38) 0.983 (0.499–1.878) 0.991
Mortality 3 (4) 0 (0) 0.882 (0.473–1.643) 0.692 1 (1) 2 (2) 1.078 (0.579–2.008) 0.812
Mortality (30 days
post-surgery)
4 (5) 1 (1) 0.789 (0.541–1.742) 0.691 2 (2) 3 (3) 1.112 (0.611–1.997) 0.828
Hospital stay, days
[median (IQR)]
9 (9–14) 9 (9–12) – 0.835 9 (9–13) 9 (9–12) – 0.415
Data are presented as N (%) unless otherwise indicated
EN enteral nutrition, IMEN immunomodulating enteral nutrition, IMPN immunomodulating parenteral nutrition, IQR interquartile range, OR
odds ratio, PN parenteral nutrition, SEN standard enteral nutrition, SPN standard parenteral nutrition
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view, it was not enough to stop there; for over 10 years the
focus has been on understanding immunologic and
inflammatory responses, so as to enhance host defense
mechanisms and improve clinical course. These activities
led to the idea of immunonutrition, a type of pharmaco-
nutrition that has been described as nutritional intervention,
not only able to provide essential nutrients to maintain
basic organ functions, but also to augment the immune
system [16]. The use of various biochemical agents, such
as non-essential (glutamine, arginine) or sulfur-containing
amino acids, omega-3-polyunsaturated fatty acids, nucle-
otides, and anti-oxidants (free radical scavengers), admin-
istered simultaneously, in few, some or alone, was assumed
to alter the host immune response [16, 17].
Several clinical trials and meta-analyses have described
the beneficial effect of perioperative administration of an
enteral or parenteral formula containing immune-ingredi-
ents on the outcome of surgery, independent of nutritional
state [18–20]. Benefits included reduction of postoperative
complications and shortening of LOS in both surgical and
critically ill patients [20–25]. These results were indepen-
dent of age, particularly when patients received admixtures
pre-operatively [26–28]. Beneficial effects were also
detected at the sub-clinical level: immunonutrition led to
an increase in immune function due to an increase in TLC,
CD4 levels, immunoglobulin (Ig)-G levels, and decrease in
interleukin (IL)-6 concentrations, and the inversion of the
correlation between IL-6 and prealbumin concentrations
after surgery [8, 9, 21]. Senkal et al. [10]. observed bene-
ficial effects of immunotherapy and even better cost
effectiveness during the late phase of recovery (defined as
the time period after postoperative day 5); at that time, the
effect of immunodiets was incontrovertible.
However, criticism came with some studies on immu-
nonutrition that were not able to demonstrate reduction of
either overall mortality or morbidity, failed to prove ben-
efits of immunonutrition, and indicated no reduction in
complications or LOS [12, 28–31]. Some authors observed
only a reduction in infectious complications without any
cost-effectiveness benefits, particularly in well-nourished
patients [30, 31]. Likewise, only some trials confirmed that
such formulas might lower the ratio of infectious compli-
cations, and a few even suggested that immunonutrition
could increase the risk of death in the critically ill [32].
There are several explanations for these inconsistencies.
Most important is the question of study group: numerous
studies in which immune-intervention presented no clinical
effect were undertaken in well-nourished patients, while
trials indicating a decrease in complications involved
moderately or severely malnourished individuals [33–35].
It was obvious that any type of surgical intervention in
malnourished patients would be beneficial, therefore results
from malnourished patients in mixed study populations
would overbalance the lack of positive results in well-
nourished patients, as proven by the fresh meta-analysis of
13 randomized, controlled trials including 1,269 patients
that demonstrated that perioperative immunonutrition in GI
surgical patients reduced rates of postoperative infection
(OR 0.41, 95 % CI 0.30–0.54), shortened LOS, and
increased several markers of immune function [4]. How-
ever, nearly all of these trials comprised patients with and
without malnutrition, and the percentage of malnourished
patients in some of them reached nearly 60 [6–8].
Table 4 Postoperative complications among study groups (part 2:
enteral nutrition in malnourished patients)





Infectious complications 60 (39.22) 43 (28.29) 0.04366
Pneumonia 45 (29.41) 33 (21.71) 0.12322
Urinary tract infection 15 (9.80) 11 (7.24) 0.42213
Surgical wound
infection
27 (17.65) 12 (7.89) 0.01077
Intra-abdominal
abscess
10 (6.54) 5 (3.29) 0.18988
Bacteremia 11 (7.19) 2 (1.32) 0.01112
Sepsis 2 (1.31) 4 (2.63) 0.40498
Other complications
Wound dehiscence 8 (5.23) 2 (1.32) 0.05502
Pancreatic fistula 10 (6.54) 4 (2.63) 0.10329
Intestinal fistula 8 (5.23) 4 (2.63) 0.24340
Duodenal fistula 1 (0.65) 2 (1.32) 0.55793
Biliary fistula 2 (1.31) 3 (1.97) 0.64672
Abdominal fluid
collection
2 (1.31) 3 (1.97) 0.64672
Delayed gastric
emptying
13 (8.50) 8 (5.26) 0.26479
Acute pancreatitis 1 (0.65) 2 (1.32) 0.55793
Intestinal obstruction 2 (1.31) 2 (1.32) 0.99473
Peritonitis 1 (0.65) 1 (0.66) 0.99629
Pulmonary embolism 2 (1.31) 1 (0.66) 0.56563
Heart failure 3 (1.96) 2 (1.32) 0.65738
Respiratory failure 7 (4.58) 5 (3.29) 0.56362
Liver failure 1 (0.65) 0 (0.00) 0.31810
Renal failure 0 (0.00) 3 (1.97) 0.08075
Neurological 1 (0.65) 1 (0.66) 0.99629
Peripheral veins
thrombosis
2 (1.31) 1 (0.66) 0.56563
GI bleeding 1 (0.65) 1 (0.66) 0.99629
Abdominal bleeding 2 (1.31) 2 (1.32) 0.99473
Mortality 9 (5.88) 2 (1.32) 0.03247
Overall morbidity 72 (47.06) 51 (33.55) 0.01621
All data are presented as N (%) unless otherwise indicated
GI gastrointestinal, IMEN immunomodulating enteral nutrition, SEN
standard enteral nutrition
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Furthermore, the heterogeneity of definitions used in
clinical studies to define simple concepts was confusing.
Kudsk et al. [33] and Lobo et al. [11]. specified these
inconsistencies: various definitions of malnutrition and co-
morbidities, imprecise timing, and route of administration;
various durations of therapy; uncontrolled execution of the
nutritional intervention; and occurrence of nutrition sup-
port-related complications [7, 36].
Another point is that many patients undergoing upper GI
surgery are at fairly low risk of fatal outcome after elective
procedures, in contrast to critically ill patients. Therefore,
ingredients such as arginine, which may be helpful in
surgical patients, can be unsafe in the latter, because the
high arginine content drives nitric oxide assembly [33].
Hence, the configuration of enteral diet plays a vital
role. Studies in which Impact (Novartis) was the tested
substance showed benefits, even in well-nourished patients,
as validated by Daly et al. [34] and Waitzberg et al. [27,
35]. It is important to bear in mind that Impact has a
specific composition: the amount of arginine in Impact is
twice as low as that in, for instance, Reconvan (Fresenius
Kabi). Furthermore, it contains no glutamine, while the
concentration of this amino acid is quite significant in
Reconvan and other enteral immunodiets. Finally, in
contrast with other diets, it also contains nucleotides.
The timing of the intervention represents another peril-
ous issue. During the postoperative period, the patient goes
through contrasting stages: systemic inflammatory
response (SIRS) and compensatory anti-inflammatory
response (CARS), which hamper maintenance of homeo-
stasis [9]. Thus, the same substance delivered pre-opera-
tively may have a useful effect since inflammatory
processes during these periods are dissimilar. It is also
easier to accomplish a nutritional plan before than after
surgery [7].
The current study was designed to confirm the hypoth-
esis that the treatment of choice, preoperative enteral
nutrition enhanced with immune ingredients, can reduce
the rate of infectious complications in surgical cancer
patients, who represent one of the most challenging groups
of patients. Study groups were perfectly homogenous in
terms of baseline characteristics, type and timing of inter-
vention, and nutritional status. We observed that, in well-
nourished patients, it was the nutritional intervention itself,
not its characteristics, that mattered the most. The median
postoperative LOS was 12.4 (SD 5.9) days in the SEN














28 (27) 25 (24) 0.81 (0.43–1.50) 0.498 25 (25) 28 (27) 1.14 (0.61–2.14) 0.672
Overall
morbidity
36 (35) 37 (36) 1.08 (0.60–1.93) 0.804 35 (35) 38 (36) 0.85 (0.48–1.50) 0.577
Mortality 2 (2) 2 (2) 0.99 (0.14–7.17) 0.992 2 (2) 2 (2) 0.95 (0.13–6.89) 0.960
Hospital stay
(days, mean)
12.8 12.5 –0.32 (–1.62 to 2.26) 0.746 12.9 12.4 –0.43 (–2.31 to 1.46) 0.656
Data are presented as N (%) unless otherwise indicated
EN enteral nutrition, OR odds ratio, PN parenteral nutrition
Table 6 Postoperative complications among study groups (part 2:
enteral nutrition in well-nourished patients)






Pneumonia 15 (16.4) 13 (14.1) [0.05
Urinary tract infection 1 (1.1) 2 (2.1) [0.05
Surgical wound infection 5 (5.5) 4 (4.2) [0.05
Abscess formation 2 (2.2) 2 (2.1) [0.05
Surgical complications
Evisceration 0 1 (1.1) [0.05
Pancreatic fistula 1 (1.1) 0 [0.05
Duodenal fistula 1 (1.1) 1 (1.1) [0.05
Jejunal fistula 2 (2.2) 1 (1.1) [0.05
Biliary fistula 0 1 (1.1) [0.05
Surgical complications overall 4 (4.4) 4 (4.4) [0.05
General complications
Pulmonary thrombosis 0 0 [0.05
Myocardial infarct 0 1 (1.1) [0.05
Peripheral vein thrombosis 0 0 [0.05
Neurological complications 0 0 [0.05
Fatal outcome 1 (1.1) 1 (1.1) [0.05
Complications overall (patients) 21 (23.1) 23 (25.2) [0.05
Uncomplicated postoperative
period (patients)
70 (76.9) 69 (75) [0.05
Data are presented as N (%) unless otherwise indicated
IMEN immunomodulating enteral nutrition, SEN standard enteral
nutrition
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group and 12.9 (SD 8.0) days in the IMEN group
(p = 0.42). Infectious complications were observed in 21
patients (23.1 %) in the SEN group and 23 (25.2 %) in the
IMEN group (p [ 0.05). The rest of the study participants
did not differ.
Conversely, in malnourished patients undergoing GI
surgery, it was possible to demonstrate the positive effect
of IMEN on treatment outcome. The most significant
clinical parameters varied markedly in favor of immuno-
nutrition. LOS was shorter: 17.1 days in the SEN group
versus 13.1 in the IMEN group; the overall morbidity (47.1
vs. 33.5 %), mortality (5.9 vs. 1.3 %), and infectious
complications (39.2 in SEN vs. 28.3 % in IMEN) were
reduced.
Neither diet influenced hepatic and renal function, vis-
ceral protein production, or immune system recovery. The
difference observed in TLC on day 3 was too slight to have
been considered clinically important.
These results reinforced the value of immunonutrition
confirmed previously in the preoperative period by Braga
et al. [8. and Gianotti et al. [9, 20], and in the postoperative
period by Zheng et al. [21] and Heyland et al. [22]. They
also support the concept that the administration of arginine-
and nucleotide-rich, glutamine-free enteral diets could be
advantageous in malnourished and even in some well-
nourished patients. However, well-nourished patients are
unlikely to gain from this management during the postop-
erative period.
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